Aquinox Pharmaceuticals Inc (AQXP) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) from a hold rating to a buy rating in a research report released on Tuesday morning. They currently have $19.00 price target on the stock.

According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “

Separately, Cantor Fitzgerald began coverage on shares of Aquinox Pharmaceuticals in a report on Friday, December 16th. They set an overweight rating and a $28.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $21.17.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 16.69 on Tuesday. The stock’s 50 day moving average is $17.93 and its 200 day moving average is $15.03. The stock’s market capitalization is $390.93 million. Aquinox Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its earnings results on Thursday, March 9th. The company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.03. Analysts anticipate that Aquinox Pharmaceuticals will post ($2.17) EPS for the current fiscal year.

Your IP Address:

In other news, major shareholder Bros. Advisors Lp Baker purchased 398,062 shares of Aquinox Pharmaceuticals stock in a transaction that occurred on Monday, January 9th. The stock was acquired at an average price of $17.18 per share, for a total transaction of $6,838,705.16. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 3.00% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of AQXP. Tower Research Capital LLC TRC increased its stake in shares of Aquinox Pharmaceuticals by 227,925.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,121 shares of the company’s stock valued at $122,000 after buying an additional 9,117 shares during the period. BlackRock Inc. increased its stake in shares of Aquinox Pharmaceuticals by 32.0% in the third quarter. BlackRock Inc. now owns 66,792 shares of the company’s stock valued at $892,000 after buying an additional 16,192 shares during the period. TD Asset Management Inc. purchased a new stake in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $1,052,000. Eventide Asset Management LLC purchased a new stake in shares of Aquinox Pharmaceuticals during the fourth quarter valued at approximately $2,889,000. Finally, BlackRock Group LTD increased its stake in shares of Aquinox Pharmaceuticals by 15.9% in the third quarter. BlackRock Group LTD now owns 232,002 shares of the company’s stock valued at $3,100,000 after buying an additional 31,902 shares during the period. Institutional investors and hedge funds own 97.78% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

5 Day Chart for NASDAQ:AQXP

Get a free copy of the Zacks research report on Aquinox Pharmaceuticals (AQXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/aquinox-pharmaceuticals-inc-aqxp-stock-rating-upgraded-by-zacks-investment-research/1708586.html

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *